Home LiteratureArticle Details
PMID: 31281549 Published · epublish English Journal Article

TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway.

Disease markers ·Vol. 2019 ·2019-00-00 ·Pages 7129214

Huang T, Chen QF, Chang BY, Shen LJ, Li W, Wu PH, Fan WJ

Abstract

Transcription factor activating enhancer binding protein 4 (TFAP4) is established as a regulator of human cancer genesis and progression. Overexpression of TFAP4 indicates poor prognosis in various malignancies. The current study was performed to quantify TFAP4 expression as well as to further determine its potential prognostic value and functional role in patients with hepatocellular carcinoma (HCC). We identified that the expression of TFAP4 mRNA in 369 tumor tissues was higher than that in 160 normal liver tissues. Upregulated TFAP4 expressions were discovered in HCC cell lines compared to the healthy liver cell line, and similarly, the levels of TFAP4 were higher in tumor tissues than its expression in paratumor tissues. High mRNA and protein expression of TFAP4 was associated with worse overall survival (OS) and disease-free survival (DFS). Additionally, TFAP4 expression emerged as a risk factor independently affecting both OS and DFS of HCC patients. Functional studies demonstrated that TFAP4 increased HCC cell migration and invasion. Further investigations found that TFAP4 promotes invasion and metastasis by inducing epithelial-mesenchymal transition (EMT) and regulating MMP-9 expression via activating the PI3K/AKT signaling pathway in HCC. In conclusion, our study demonstrated that TFAP4 is a valuable prognostic biomarker in determining the likelihood of tumor metastasis and recurrence, as well as the long-term survival rates of HCC patients. Exploring the regulatory mechanism of TFAP4 will also contribute to the development of new prevention and treatment strategies for HCC.

MeSH Terms
Biomarkers, Tumor/genetics,metabolism Carcinoma, Hepatocellular/genetics,metabolism,pathology Cell Line, Tumor DNA-Binding Proteins/genetics,metabolism Disease-Free Survival Epithelial-Mesenchymal Transition Female Humans Liver Neoplasms/genetics,metabolism,pathology Male Matrix Metalloproteinase 9/genetics,metabolism Middle Aged Neoplasm Invasiveness Neoplasm Metastasis Phosphatidylinositol 3-Kinases/metabolism Proto-Oncogene Proteins c-akt/metabolism Signal Transduction Transcription Factors/genetics,metabolism Up-Regulation
Chemicals
Biomarkers, Tumor DNA-Binding Proteins Transcription Factors enhancer-binding protein AP-4 Proto-Oncogene Proteins c-akt MMP9 protein, human Matrix Metalloproteinase 9
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Huang Tao
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Chen Qi-Feng
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Chang Bo-Yang
Department of Vascular Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Shen Lu-Jun
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Li Wang ORCID
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Wu Pei-Hong ORCID
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Fan Wei-Jun ORCID
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
References (33)
33 references, click to expand
  1. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.
    J Hepatol. 2001 Apr;34(4):570-5 PMID: 11394657
  2. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.
    Clin Chim Acta. 2001 Nov;313(1-2):15-9 PMID: 11694234
  3. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.
    World J Gastroenterol. 2001 Oct;7(5):630-6 PMID: 11819844
  4. An overview of the basic helix-loop-helix proteins.
    Genome Biol. 2004;5(6):226 PMID: 15186484
  5. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.
    Oncogene. 2005 Nov 14;24(50):7443-54 PMID: 16288291
  6. Matrix metalloproteinases and tumor metastasis.
    Cancer Metastasis Rev. 2006 Mar;25(1):9-34 PMID: 16680569
  7. The Oscar-worthy role of Myc in apoptosis.
    Semin Cancer Biol. 2006 Aug;16(4):275-87 PMID: 16945552
  8. AP4 encodes a c-MYC-inducible repressor of p21.
    Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15046-51 PMID: 18818310
  9. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?
    Dig Dis Sci. 2009 May;54(5):1015-20 PMID: 19058005
  10. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
    Gastroenterology. 2009 Jul;137(1):110-8 PMID: 19362088
  11. Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
    Nat Rev Cancer. 2009 Aug;9(8):550-62 PMID: 19629070
  12. Present and future possibilities for early diagnosis of hepatocellular carcinoma.
    World J Gastroenterol. 2010 Jan 28;16(4):418-24 PMID: 20101765
  13. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.
    Gut. 2010 Dec;59(12):1687-93 PMID: 20876776
  14. Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity.
    Genes Dev. 1990 Oct;4(10):1741-52 PMID: 2123466
  15. The overexpression of AP-4 as a prognostic indicator for gastric carcinoma.
    Med Oncol. 2012 Jun;29(2):871-7 PMID: 21336989
  16. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience.
    Ann Surg. 2011 Apr;253(4):745-58 PMID: 21475015
  17. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer.
    J Exp Med. 2013 Jul 1;210(7):1331-50 PMID: 23752226
  18. Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-κB and AP-1 activity in human liver cancer cells.
    Br J Pharmacol. 2014 Jun;171(12):3037-50 PMID: 24641665
  19. AP‑4 predicts poor prognosis in non‑small cell lung cancer.
    Mol Med Rep. 2014 Jul;10(1):336-40 PMID: 24804973
  20. NFκB- and AP-1-mediated DNA looping regulates matrix metalloproteinase-9 transcription in TNF-α-treated human leukemia U937 cells.
    Biochim Biophys Acta. 2015 Oct;1849(10):1248-59 PMID: 26260845
  21. Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.
    Cancer Lett. 2016 Jan 1;370(1):56-65 PMID: 26454215
  22. 14-3-3β Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells by Modulating Expression of MMP2 and MMP9 through PI3K/Akt/NF-κB Pathway.
    PLoS One. 2016 Jan 05;11(1):e0146070 PMID: 26730736
  23. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    APMIS. 2016 Mar;124(3):208-15 PMID: 26764243
  24. 14-3-3ζ up-regulates hypoxia-inducible factor-1α in hepatocellular carcinoma via activation of PI3K/Akt/NF-кB signal transduction pathway.
    Int J Clin Exp Pathol. 2015 Dec 01;8(12):15845-53 PMID: 26884855
  25. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.
    Int J Cancer. 2016 Oct 1;139(7):1534-45 PMID: 27244487
  26. Emerging Biological Principles of Metastasis.
    Cell. 2017 Feb 9;168(4):670-691 PMID: 28187288
  27. Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients.
    Exp Ther Med. 2017 Oct;14(4):3057-3061 PMID: 28912857
  28. AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin.
    Cell Death Dis. 2017 Oct 5;8(10):e3060 PMID: 28981098
  29. The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression.
    Mol Cancer Res. 2018 May;16(5):857-868 PMID: 29378908
  30. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
    Cancer Sci. 2018 May;109(5):1414-1427 PMID: 29603830
  31. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Jul;69(1):182-236 PMID: 29628281
  32. Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinoma.
    Theranostics. 2018 Jun 7;8(13):3571-3583 PMID: 30026867
  33. The transcription factor Krüppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma.
    Biochem Biophys Res Commun. 2019 Jan 1;508(1):159-168 PMID: 30473218
Article Info
Journal
Disease markers
Abbr.
Dis Markers
ISSN
1875-8630
Published
2019-00-00
Epub
2019-00-10
Pages
7129214
Language
English
Region
United States
NLM ID
8604127
PMCID
PMC6590577
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com